Pulmonx Q4 revenue $13.7M (+39% YoY); FY rev $48.4M (+48%); guides FY22 $55-60M

Pulmonx Corp

2021-FY EPS reported -$1.35 revenue$48,416,000

Q4 net loss $13.0M ($0.35/sh) vs $9.3M ($0.27/sh) YoY; FY net loss $48.7M ($1.35/sh) vs $32.2M ($3.16/sh).
Q4 gross margin 74.8% (vs 72.0% YoY); FY gross margin 73.6% (vs 64.8%); improvement from production efficiencies.
U.S. treatment centers for Zephyr Valves expanded to 214, a 45% increase since start of 2021.
FY 2022 revenue guidance $55-60M; Q1 2022 revenue expected $9-10M due to COVID impact.
Regulatory submission for Zephyr Valve approval in Japan made in December 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.